ArticleInfection2015
Economic burden of Clostridium difficile associated diarrhoea: a cost-of-illness study from a German tertiary care hospital.
Article in Infection, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 1 synthesis or guideline pooled it, 49 citations in OpenAlex.
- A Systematic Literature Review of Economic Evaluations of Antibiotic Treatments for Clostridium difficile Infection.PharmacoEconomics · 2017Pooled it
- Thirty-Day Readmissions in Hospitalized Patients Who Received Bezlotoxumab With Antibacterial Drug Treatment for Clostridium difficile Infection.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2017Trial
- Article
- Epidemiology and Course of Clostridioides difficile Infections in Germany: Retrospective Analysis of German Health Claims Data.Infectious diseases and therapy · 2025Article
- Association of antimicrobial consumption withInfection prevention in practice · 2025Article
- Mechanisms ofFrontiers in cellular and infection microbiology · 2025Review
- Costs and Outcomes of Clostridioides difficile Infections in Germany: A Retrospective Health Claims Data Analysis.Infectious diseases and therapy · 2025Article
- Estimating excess mortality and economic burden of Clostridioides difficile infections and recurrences during 2015-2019: the RECUR Germany study.BMC infectious diseases · 2024Article
- Article
- A budget impact analysis of bezlotoxumab versus standard of care antibiotics only in patients at high risk of CDI recurrence from a hospital management perspective in Germany.BMC health services research · 2021Article
- Analysis of C. difficile infection-related outcomes in European participants in the bezlotoxumab MODIFY I and II trials.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2020Article
- Exploratory Evaluation of Bezlotoxumab on Outcomes Associated WithOpen forum infectious diseases · 2020Article
- The Economic Burden ofFrontiers in public health · 2020Article
- Cost savings following faecal microbiota transplantation for recurrentTherapeutic advances in gastroenterology · 2019Article
- Inpatient Expenditures Attributable to Hospital-Onset Clostridium difficile Infection: A Nationwide Case-Control Study in Japan.PharmacoEconomics · 2018Article
- Bezlotoxumab Is Associated With a Reduction in Cumulative Inpatient-Days: Analysis of the Hospitalization Data From the MODIFY I and II Clinical Trials.Open forum infectious diseases · 2018Article
- Attributable Healthcare Resource Utilization and Costs for Patients With Primary and Recurrent Clostridium difficile Infection in the United States.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2018Observational
- Recent Progress for the Effective Prevention and Treatment of RecurrentInfectious diseases · 2018Article
- Surveillance of antibiotic resistance among common Clostridium difficile ribotypes in Hong Kong.Scientific reports · 2017Article
- [Bezlotoxumab for the secondary prevention of Clostridium difficile infection : MODIFY I and MODIFY II studies].Der Internist · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeClostridium difficile associated diarrhoea (CDAD) is the most common cause of health-care-associated infectious diarrhoea. In the context of the German health-care system, direct and indirect costs of an initial episode of CDAD and of CDAD recurrence are currently unknown.
methodsWe defined CDAD as presence of diarrhoea (≥3 unformed stools/day) in association with detection of Clostridium difficile toxin in an unformed faecal sample. Patients treated with metronidazole (PO or IV) and/or vancomycin (PO) were included. Comprehensive data of patients were retrospectively documented into a database using the technology of the Cologne Cohort of Neutropenic Patients (CoCoNut). Patients with CDAD were matched to control patients in a 1:1 ratio. Analysis was split in three groups: incidence group (CDAD patients without recurrence), recurrence group (CDAD patients with ≥1 recurrence) and control group (matched non-CDAD patients).
resultsBetween 02/2010 and 12/2011, 150 patients with CDAD (114 patients in the incidence and 36 (24 %) in the recurrence group) and 150 controls were analysed. Mean length of stay was: 32 (95 %CI: 30-37), 94 (95 %CI: 76-112) and 24 days (95 %CI: 22-27; P = <0.001), resulting in mean overall direct treatment costs per patient of €18,460 (95 %CI: €14,660-€22,270), €73,900 (95 %CI: €50,340-€97,460) and €14,530 (95 %CI: €11,730-€17,330; P = <0.001). In the incidence and recurrence group, the mean cumulative number of antibiotic CDAD treatment days was 11 (95 %CI: 10-12) and 36 (95 %CI: 27-45; P = <0.001).
conclusionsEspecially CDAD recurrence was associated with excessive costs, which were mostly attributable to a significantly longer overall length of stay. Innovative treatment strategies are warranted to reduce treatment costs and prevent recurrence of CDAD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.